# Research and Education towards Solutions for Late effects to Innovate, Excel, and Nurture after chronic Graft-versus-Host Disease (RESILIENT after cGVHD)

> **NIH NIH R13** · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $36,500

## Abstract

Project Summary/ Abstract
 The overarching goal of the Research and Education towards Solutions for Late effects
to Innovate, Excel, and Nurture after chronic Graft-versus-Host Disease (RESILIENT after
cGVHD) consensus conference is to address the 1) state of the science, 2) recommendations for
clinical care, and 3) research priorities for pediatric survivors of Hematopoetic cell transplantation
(HCT) diagnosed with cGVHD. The conference is expected to include approximately 150-200
members/ stakeholders of the pediatric HCT community. This one day conference will take place
in the same location, and one day prior to the start of the annual to the American Society of
Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow
Transplantation Research (CIBMTR) Tandem Meetings, the largest HCT meeting in North
America. The RESILIENT after cGVHD consensus conference is being led by the Pediatric
Transplantation and Cellular Therapy (PTCTC) Late-Effects and Graft-versus-Host Disease
strategy groups. Prior to the conference four working comittees have been formed to develop key
topics for long-term survivors with cGVHD: 1) Phases of cGVHD, 2) Organ Dysfunction and
Immunity, 3) Metabolism, Growth and Development, and 4) Patient Important Outcomes. Each
working group is co-lead by a member with expertise in GVHD and a member with expertise in
survivorship, and includes 5-7 additional members. Meticulous attention has been paid to ensure
the composition of working committees represents experts with diverse backgrounds based on
several criteria including: career stage, race, gender, and ethnicity, geographic location across
the United States and Canada, HCT program size (i.e. how many HCTs are performed each year,
is the program part of a single health system or a standalone children’s hospital), and credentials
(e.g. inclusion of pharmacists, psychologists, nurses, physician assistants, physicians, physical
therapist). Working group diversity also encompasses experts in research and clinical care to
promote both advances in clinical care that could be adapted quickly and broad research
questions that could be addressed through collaborations in these groups. The working
committees will present their preliminary findings at the consensus conference which will then be
followed by a forum for open discussion. Finally, manuscripts from each working group will be
submitted for peer-reviewed publication and dissemination throughout the HCT Community.

## Key facts

- **NIH application ID:** 10823735
- **Project number:** 1R13HL172559-01
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** seth J rotz
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $36,500
- **Award type:** 1
- **Project period:** 2024-01-01 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10823735

## Citation

> US National Institutes of Health, RePORTER application 10823735, Research and Education towards Solutions for Late effects to Innovate, Excel, and Nurture after chronic Graft-versus-Host Disease (RESILIENT after cGVHD) (1R13HL172559-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10823735. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*